Chappuy Hélène, Doz François, Blanche Stéphane, Gentet Jean-Claude, Tréluyer Jean-Marc
Département d'Urgences Pédiatriques, Hôpital Necker Enfants Malades, Assistance Publique Hopitaux de Paris et Laboratoire d'Ethique Médicale Université René Descartes Paris, France.
Pediatr Blood Cancer. 2008 May;50(5):1043-6. doi: 10.1002/pbc.21359.
To examine the level of children's understanding of informed consent in clinical trials and factors that may influence these processes.
Twenty nine children who were included in clinical trials for treatment of cancer or HIV, were offered the possibility to complete a semidirective interview, with parental permission.
Children's understanding was measured by a score of 0-9 including items required to obtain a valid consent according to French and European legislations.
Children were 8.5-18 years old (13.6 +/- 2.8 years). The higher percentage of understanding was obtained for the study objectives (n = 18, 62%), the risks (n = 17, 58%), the potential self-benefits (n = 18, 62%) and the potential benefits to other children (n = 17, 58%). The lower percentage of understanding was obtained for the procedures (n = 5, 17%), the possibility of alternative treatments (n = 9, 31%), the duration of participation (n = 6, 21%), their right to withdraw (n = 6, 21%), and the voluntary participation (n = 6, 21%). Sixteen children (55%) thought that the given information was adequate. Understanding was significantly correlated with child's age (r = 0.65; P = 0.0001) and the mean score was higher in patients over 14 years old compared to patients under the age of 14 (4.4 +/- 2.4, n = 14 vs. 2.6 +/- 2.6, n = 15, P < 0.05). The mean score was also higher in children when informed consent was sought some time after the diagnosis (>7 days) rather than at the same time (<7 days) (score: 4.14 +/- 2.59 n = 21 vs. 1.87 +/- 2.03 n = 8; P = 0.03). The clarity of information perceived by children did not influence their understanding (score: 3.6 +/- 2.6 n = 14 vs. 3.5 +/- 2.7 n = 15; P = 0.91).
Children have an incomplete understanding of the elements included in the informed consent forms. Understanding is related to age and timing of informed consent.
探讨儿童对临床试验中知情同意的理解程度以及可能影响这些过程的因素。
29名参与癌症或艾滋病治疗临床试验的儿童,在获得家长许可后,有机会完成一次半指导性访谈。
根据法国和欧洲立法,通过0至9分的评分来衡量儿童的理解程度,评分项目包括获得有效同意所需的内容。
儿童年龄在8.5至18岁之间(平均13.6±2.8岁)。对研究目的(n = 18,62%)、风险(n = 17,58%)、潜在自身益处(n = 18,62%)和对其他儿童的潜在益处(n = 17,58%)的理解比例较高。对程序(n = 5,17%)、替代治疗的可能性(n = 9,31%)、参与持续时间(n = 6,21%)、退出权利(n = 6,21%)和自愿参与(n = 6,21%)的理解比例较低。16名儿童(55%)认为所提供的信息足够。理解程度与儿童年龄显著相关(r = 0.65;P = 0.0001),14岁以上患者的平均得分高于14岁以下患者(4.4±2.4,n = 14 vs. 2.6±2.6,n = 15,P < 0.05)。在诊断后一段时间(>7天)而不是同时(<7天)寻求知情同意时,儿童的平均得分也较高(得分:4.14±2.59,n = 21 vs. 1.87±2.03,n = 8;P = 0.03)。儿童所感知信息的清晰度并未影响他们的理解(得分:3.6±2.6,n = 14 vs. 3.5±2.7,n = 15;P = 0.91)。
儿童对知情同意书中包含的内容理解不完整。理解程度与年龄及知情同意的时机有关。